The 2026-indexed review listed by the U.S. National Library of Medicine/PubMed found robust support for oral spironolactone in adult female acne. For teens with inflammatory acne, that means proven treatments come first and topical spironolactone stays experimental.
Topical spironolactone is an anti-androgen mixture applied to skin to curb hormone-driven oil and breakouts. Inflammatory acne means red papules and pustules, the sore bumps that matter most for teen choices. Acne vulgaris affects about 80% of teenagers, according to a University of Nottingham professional survey survey of clinicians treating patients 18 and younger.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Why Is the Evidence Called Limited?
- What Did Small Trials Find?
- How Does Winlevi Compare?
- What Should Teens Do Now?
Why Is the Evidence Called Limited?
The Journal of Clinical and Aesthetic Dermatology review points to size and formula chaos. Trials used small groups and different bases, strengths, and dosing schedules. It calls for pharmacokinetic studies plus large randomized trials before routine use.
The split matters. Oral data centers on adult women with hormonal patterns. Teen data are thinner, so adult results do not transfer cleanly.
What Did Small Trials Find?
A January 2025 meta-analysis listed on PubMed pooled 7 randomized trials in 643 patients. Five percent spironolactone cut total lesions by 6.85 versus placebo. It also cut acne severity index by 6.33.
An earlier systematic review covered 5 trials in 195 patients, reported by Dove Medical Press. It found fewer papules, closed comedones, and total lesions than placebo. A 2% solution beat clindamycin for comedones, papules, and pustules in that set.
How Does Winlevi Compare?
Clascoterone 1% cream offers a contrast, according to Drugs.com FDA history. Winlevi won FDA approval in August 2020 for acne vulgaris at age 12 and older. Approval followed two phase 3 trials plus long-term safety data in over 1,700 patients.
A 2023 Journal of Dermatological Treatment review reports topical spironolactone lacks FDA approval for acne vulgaris. Its review says efficacy has not met regulatory standards. Oral spironolactone is also off-label but holds conditional guideline support.
What Should Teens Do Now?
A City Skin Clinic clinician review translates this for inflamed teen acne. It advises proven age-appropriate topicals, antibiotics, retinoids, or Winlevi first.
It frames compounded topical spironolactone as experimental to discuss with a dermatologist. Use visits to compare options directly. Bring every product you use to that visit, including moisturizers and compounded mixes.
- Stay on the prescribed retinoid, benzoyl peroxide, or combination unless the doctor changes it
- Track sore red bumps, pus bumps, pain, and new scars
- Ask about Winlevi eligibility, antibiotic need, and non-compounded choices
- Do not order compounded spironolactone on your own
You Might Also Like
- Topical Hormonal Acne Treatments in a 2026 Review: What the Findings Mean for Teens With Inflammatory Acne
- Topical Clascoterone Evidence Revisited in 2026: What the Findings Mean for Teens With Inflammatory Acne
- Omega-3 Balance and Acne Questions in the 2026 Diet Review: Associations, Trials, and Evidence Gaps for Teens With Acne